Annual Investment Trends in HIV Prevention Research and Development
Global preventive AIDS vaccine R&D investment totaled US$818 million in 2013, with the public sector providing US$666 million (81%), the philanthropic sector providing US$121 million (15%), and the commercial sector contributing US$31 million (4%). The 2013 total investment represents a decrease of US$29 million (4%) below global preventive AIDS vaccine R&D investment in 2012.
The United States government remained by far the largest investor in AIDS vaccines, providing US$585 million in 2013, even though total U.S. government funding decreased by US$38 million from 2012, driven by mandated across-the-board federal budget cuts. Funding from European public sector agencies totaled US$44 million, after reductions of almost US$8 million (15%) from 2012. Funding from philanthropic supporters for AIDS vaccines grew by around US$10 million dollars (approximately 10%) from 2012 to 2013. Meanwhile, estimated commercial funding in 2012 remained relatively flat at US$31 million.
The AIDS vaccine field has produced an abundance of promising data in recent years. However, given the long-term nature of AIDS vaccine development, its continued progress will require flexible and sustained investments in research and development.
This data was collected by the HIV Vaccines and Microbicides Resource Tracking Working Group, founded in 2004 to track global resources dedicated to the research and development of new biomedical tools for HIV prevention. The Working Group is a collaboration between AVAC: Global Advocacy for HIV Prevention, IAVI, and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Funding data assembled by the Working Group date back to 2000 and have enabled the systematic tracking of investments and trends in the advancement of new tools and strategies to prevent HIV.
The Working Group’s most recent report, HIV Prevention Research & Development Investment in 2013: In a changing global development, economic, and human rights landscape, was issued in July 2014. It covers investments through 2013 on preventive and therapeutic vaccines against HIV, microbicides, adult male circumcision, female condoms, pre-exposure prophylaxis (PrEP), and HSV-2 prevention, as well as developing and improving strategies for prevention of mother-to-child vertical HIV transmission at birth and during breastfeeding.
AIDS Vaccine Funding, 2000-2013
For more information on the Working Group, archived reports and materials, and information on its members, please visit http://www.hivresourcetracking.org.